Anika Therapeutics (ANIK) Interest Coverage Ratio (2012 - 2026)
Anika Therapeutics' (ANIK) quarterly Interest Coverage Ratio came in at 3.29 in Q1 2026, down 100.51% on a QoQ basis from 646.0 in Q4 2025.
Anika Therapeutics (ANIK) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 10 years of Interest Coverage Ratio data on file, last reported at 3.29 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio changed N/A year-over-year to 3.29 in Q1 2026; TTM through Mar 2026 was 7.36, a N/A change from a year earlier, with the FY2025 full-year figure at 0.24, down 114.59% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 3.29, down from 646.0 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for ANIK reached as high as 646.0 in Q4 2025 and fell as low as 4180.0 in Q2 2025.
- Historically, Interest Coverage Ratio has averaged 269.99 across 5 years, with a median of 3.16 in 2026.
- On a YoY basis, Interest Coverage Ratio climbed as much as 4137065.67% in 2025 and fell as far as 69181.77% in 2025.
- Year by year, Interest Coverage Ratio stood at 0.62 in 2022, then surged by 31704.37% to 194.5 in 2023, then slumped by 100.01% to 0.02 in 2024, then jumped by 4137065.67% to 646.0 in 2025, then tumbled by 100.51% to 3.29 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 3.29 in Q1 2026, 646.0 in Q4 2025, and 4180.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn | -3.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.29 |
| Dec 31, 2025 | 646.00 |
| Jun 30, 2025 | -4,180.00 |
| Dec 31, 2024 | -0.02 |
| Sep 30, 2024 | -0.33 |
| Jun 30, 2024 | -6.03 |
| Mar 31, 2024 | -7.93 |
| Dec 31, 2023 | 194.50 |
| Sep 30, 2023 | -3.34 |
| Jun 30, 2023 | -3.03 |
| Mar 31, 2023 | -19.86 |
| Sep 30, 2022 | -0.62 |
| Jun 30, 2022 | -1.10 |
| Mar 31, 2022 | -394.89 |
| Dec 31, 2021 | 41.47 |
| Sep 30, 2021 | 0.28 |
| Mar 31, 2021 | 5.72 |
| Dec 31, 2020 | -35.91 |
| Sep 30, 2020 | -15.85 |
| Jun 30, 2020 | -4.49 |